DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/8081c8/the_pharmaceutical) has announced the addition of the "The Pharmaceutical Market: Switzerland" report to their offering.
Politically, the coalition government has remained stable, despite the economic crisis. The Swiss economy entered recession in 2009, but GDP did return to positive growth in the third quarter. Although recovery is set to be gradual, overall the Swiss economy has experienced a much shallower downturn than other Western European countries. This is a positive macroenvironment for drug sales and demand.
The Swiss pharmaceutical industry is highly advanced and has long had an international reputation for the quality of its production and research. Two local companies dominate the sector; Novartis and Roche. They are both prominent in the domestic market, although the majority of their sales are earned outside Switzerland. Swiss exports of pharmaceutical products exceed US$40 billion; the balance of pharmaceutical trade is positive and has demonstrated an upward trend since 2000.
By international standards the Swiss generics market remains uncompetitive. Over 70% of generic sales are made by two companies; Mepha, acquired by Cephalon in April 2010, and Sandoz. A more competitive environment would almost certainly lead to lower price levels. However, the governments policy of period price reductions may prove counterproductive in this regard, by making the market less attractive for new players and entrenching the position of the existing manufacturers. A few other companies, notably Teva, Actavis and sanofi-aventis (through Winthrop), are active in the market, but to date have not gained much market share.
There are several acquisitions in the pipeline. Novartis is hoping to acquire the remaining 23% minority stake in an Australian-based eye care company, after buying the majority stake earlier this year. However, the Australian company's independent director committee has called for Novartis to raise its offer to minority shareholders but it has so far refused to do so. In the biologic sector, Actelion entered a binding agreement in July 2010 to acquire a French company, which specialises in neurodegenerative diseases.
These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context.
The reports provide:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
Key Topics Covered:
- Highly Detailed Report Content
- Executive Summary
- Regulatory Affairs
- Pricing & Reimbursement
- Distribution Channels
- Market Analysis
- OTC Pharmaceuticals
- Generic Pharmaceuticals
- Biologics & Biosimilars
- Opportunities & Challenges
- Methodology & Sources
- Boehringer-Ingelheim (Schweiz) GmbH
- Cilag AG
- Dr. Grossmann AG Pharmaca
- Siegfried CMS AG
- Tillotts Pharma AG
- Trichema AG
- Acino Pharma (formerly Cimex)
- Sandoz Pharmaceuticals
- Streuli Pharma
- Amedis-UE AG
- Galenica Holding
- Voigt AG
For more information visit http://www.researchandmarkets.com/research/8081c8/the_pharmaceutical
Source: Espicom Business Intelligence Ltd
Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
KEYWORDS: Europe Switzerland
INDUSTRY KEYWORDS: Health Pharmaceutical